Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mallinckrodt, FTC And The Antitrust Risks Of Pipeline Acquisitions

Executive Summary

Acthar case could discourage firms looking to enhance franchises by acquiring drugs in development after FTC alleges firm purchased a would-be competitor to keep it off the US market. Is this something else we can blame on Martin Shkreli?


Related Content

Shkreli's Indictment May Help Industry Escape His Shadow
Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts